secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2025-01-27T23:59:59+00:00
Accession:  0000950170-25-009225
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atara Biotherapeutics cuts workforce by ~50%; expects $7.5M severance costs
---------------------------------------------------------------------------

- Workforce reduction impacts ~50% of current employees; completion expected by June 2025.
- Estimated severance and related benefits of approximately $7.5 million, primarily one-time cash charges.
- Additional details to be disclosed in Q1 2025 Form 10-Q.
- Company may incur other charges not currently contemplated from the reduction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000095017025009225/0000950170-25-009225-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000095017025009225/atra-20250127.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-009225

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer